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Defects in the completion of cell division by cytokinesis have long been proposed to foster carcinogenesis by
engendering chromosome instability, but few tumor suppressor mechanisms controlling this process have so far been
identiﬁed. Here, we identify a carboxyl (C)-terminal region of the high-mobility group protein HMG20b that is essential
for cytokinesis, and report that it is inactivated by a cancer-associated mutation. We ﬁnd that a C-terminal region of
HMG20b spanning residues 173–317 is necessary and sufﬁcient not only for its localization to cytokinetic structures, but
also for its interaction with the tumor suppressor BRCA2, implicated in the abscission step of cytokinesis. Indeed,
expression of this C-terminal HMG20b region sufﬁces to restore cytokinesis in HMG20b-depleted cells. The non-
conservative substitution of HMG20b residue Ala247 with Pro, reported in human lung cancer, disrupts these activities
of HMG20b, impairing cytokinesis in a trans-dominant manner. Our ﬁndings provide fresh insight into the mechanism
by which the HMG20b-BRCA2 complex controls mitotic cell division, and implicate heterozygous HMG20b mutations
affecting cytokinesis regulation in the genesis of human cancers.
Introduction
A long-standing hypothesis concerning human carcinogenesis
is that the failure of cell division, which generates polyploid cells
containing an abnormally high number of chromosomes, can
provoke the formation of aneuploid tumors.1-4 Normally,
mitotic cell division culminates in cytokinesis, during which the
cellular and genetic complement of a cell is divided equally into
2 daughters (reviewed in 5,6). Cytokinesis begins when a cortical,
actomyosin-based contractile ring forms at the equator of the
dividing cell following the metaphase-to-anaphase transition,
which subsequently constricts during anaphase to form a struc-
ture called the cleavage furrow. The cleavage furrow eventually
compacts the central region of the mitotic spindle into the mid-
body, which forms part of a narrow intracellular bridge that is
cleaved during abscission to complete the physical separation of
the daughter cells. Surprisingly, whereas there is growing insight
into the molecules and mechanisms involved in contractile ring
formation, cell cleavage and abscission during mitosis, few of
these mechanisms have so far been connected to human
carcinogenesis.7,8
Here, we report evidence that implicates HMG20b, a ubiqui-
tously expressed protein of uncertain function, in tumor suppres-
sion through an essential role performed by its carboxyl (C)-
terminal region in cytokinesis. HMG20b was first isolated as a
member of the high-mobility group (HMG) of non-sequence-
specific DNA binding proteins,9 contains an N-terminal HMG
domain and a C-terminal coiled-coil region. Little is known of
HMG20b’s biological functions. It has previously been reported
to decorate condensed mitotic chromosomes and regulate cell
cycle progression from G2 into mitosis,10 to repress the expres-
sion of neuronal genes through participation in a histone-deacty-
lase complex,11,12 and to bind to BRCA2, a hereditary breast and
ovarian cancer suppressor protein,10,13 to regulate cell division by
cytokinesis.13 We have investigated the mechanism by which
the BRCA2-HMG20b complex regulates cell division, and
© MiYoung Lee and Ashok R Venkitaraman
*Correspondence to: Ashok R Venkitaraman; Email: arv22@mrc-cu.cam.ac.uk
Submitted: 02/06/2014; Revised: 06/03/2014; Accepted: 06/03/2014
http://dx.doi.org/10.4161/15384101.2014.942204
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The
moral rights of the named author(s) have been asserted.
2554 Volume 13 Issue 16Cell Cycle
Cell Cycle 13:16, 2554--2563; August 15, 2014; Published with license by Taylor & Francis Group, LLC
REPORT
demonstrate here that the C-terminal region of HMG20b is nec-
essary and sufficient for complex formation with BRCA2, for
localization to cytokinetic structures, and for the restoration of
cytokinesis in HMG20b-depleted cells. Interestingly, a non-
conservative substitution of Ala247 to Pro within this critical
HMG20b region, recently reported in human lung cancer, suffi-
ces to inactivate these activities of HMG20b. Collectively, our
findings define a mechanism that regulates normal cell division
by cytokinesis, and its disruption by a cancer-associated mutation.
Results
The C-terminal region of HMG20b mediates binding to the
BRC5 motif in BRCA2
To investigate further how complex formation between
HMG20b and BRCA2 regulates cytokinesis, we defined the
region within HMG20b required for this interaction. Human
HMG20b contains at its amino (N)-terminus at amino acids (aa)
69–139 (Fig. 1A) a high mobility group (HMG) domain, impli-
cated in non-sequence specific DNA binding. In silico structural
analysis also predicted the presence of a kinesin-like coiled coil
(KLCC) domain, consisting of a heptamer repeat similar to a leu-
cine zipper, spanning aa238–305.10,14 However, more recently
developed coiled-coil predicting programs, Pair Coil 2 and
COILS15,16 predict a more extensive coiled-coil domain extend-
ing across aa114–143 and 192–262 (Fig. 1A), forming a bundle
of a-helices that may provide interfaces for the dynamic assembly
of protein complexes.17 We therefore designed a series of trun-
cated fragments of HMG20b protein, including or excluding the
predicted coiled-coil domain (Fig. 1A) and encoding C-terminal
6xHis tags, to test the importance of the domain in complex for-
mation with BRCA2. These His-tagged HMG2b fragments were
expressed in E. coli and purified using a nickel-charged affinity
resin (Fig. 1C). We have previously shown13 that HMG20b
binds to the BRC5 repeat motif spanning residues 1661–1695
within human BRCA2. Notably, 2 C-terminal HMG20b frag-
ments (spanning aa113–317 and aa173–317) exhibited
Figure 1. The C-terminal region of HMG20b mediates complex formation with BRCA2. (A) Domain structure of HMG20b and design of N-terminal and
C-terminal HMG20b fragments. The boundaries are shown as amino acid residue numbers. Binding afﬁnity for BRC5 is shown next to each fragment. (B)
Relative binding afﬁnity of each HMG20b fragment for BRC5 repeat. Binding afﬁnity was calculated by dividing band intensities of bound fractions by
those of input. Relative binding afﬁnity of each fragment compared to the full-length protein is shown as means § s.e.m. from 3 independent experi-
ments. Each HMG20b fragment is compared with the full-length HMG20b by Dunnett’s multiple comparison test (**: 0.001 < P < 0.01, *: 0.01 < P <
0.05, ns: P > 0.05). (C) Coomassie brilliant blue staining of gel showing puriﬁed HMG20b fragments (marked with an asterisk). (D) C-terminal region of
HMG20b mediates binding to BRC5 motif. Coomassie brilliant blue staining of gel from Streptavidin pull-down assay. HMG20b fragments bound to
Biotin-BRC5 peptide are marked with an asterisk. BSA included in excess amount in the binding buffer appears after staining of the gel.
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significant binding to a biotinylated peptide encoding the BRC5
motif (Fig. 1B and D). These findings define the HMG20b
region spanning residues 173–317 as the minimal region
required for complex formation with the BRC5 repeat of
BRCA2.
We further dissected this minimal region aa173-317 (Fig. S1)
by serial truncation from the C-terminus. Whereas the aa173–
276 fragment retained BRC5 binding, further truncation (frag-
ment aa173–264) caused a reduction in the binding activity.
Moreover, the short fragment at the extreme C-terminus of
HMG20b (aa 265–317) did not bind to the BRC5 repeat
(Fig. S1B and D).
Collectively, our results identify the region between HMG20b
residues 173–276 as the minimal requirement for efficient binding
to the BRC5 repeat of BRCA2. Although the predicted coiled-coil
domain (aa192–262) falls within this minimal region, a shorter
fragment aa173–264, which also contains the coiled-coil domain,
exhibits reduced binding activity. Also, the upstream coiled-coil
region (114–143) was not required for the binding to the BRC5
repeat. These results indicate that the coiled-coil structure alone is
insufficient for HMG20b-BRCA2 binding, and that additional
features within HMG20b also cooperate.
The C-terminal region of HMG20b mediates midbody
localization
BRCA2 is recruited to the midbody by the actin-binding pro-
tein Filamin A, which is required for subsequent recruitment of
the endosomal sorting complex required for transport (ESCRT)
components, Alix, and Tsg101 to the midbody and formation of
CEP55-Alix and CEP55-Tsg101 complexes during abscission.18
Whether HMG20b also localizes to the midbody has not yet
been ascertained. To address this issue, we created HeLa cell lines
which express Tetracycline (Tet)-inducible constructs encoding
HMG20b tagged at its N-terminus with enhanced green fluores-
cent protein (GFP). We find that GFP-HMG20b is nuclear dur-
ing interphase. Upon entry into mitosis, HMG20b redistributes
to the whole cell area with slight concentration on the mitotic
spindle (Fig. 2A). However, it is excluded from condensed chro-
mosomes (Fig. 2A, Fig. S2), in contrast to a previous report by
Marmorstein et al.10 HMG20b is finally recruited to the cytoki-
netic midbody during telophase (Fig. 2A), which is consistent
with the proposed function for the HMG20b-BRCA2 complex
in abscission.13
HMG20b localization to the cytokinetic midbody during
telophase was also verified by staining for the endogenously
expressed HMG20b protein. The monoclonal antibody clone
IF6 specifically recognizes a single band corresponding to the
expected molecular weight of HMG20b in Western blotting,
which is depleted following exposure to HMG20b siRNA
(Fig. 3A). Indeed, IF6 staining decorates the midbody, and is
specifically reduced following HMG20b depletion (Fig. 3B, C).
These results provide evidence that endogenous HMG20b, as
well as GFP-HMG20b, localize to the cytokinetic midbody.
Interestingly, GFP-HMG20b co-staining with midbody
markers such as MKLP1 and Cep55 not only confirms midbody
localization, but also suggests that Cep55 and HMG20b occupy
distinct topologic domains within the structure. Whereas the spa-
tial overlap between GFP-HMG20b and MKLP staining is virtu-
ally complete (Fig. S3A), Cep55 and GFP-HMG20b only partly
coincide, suggesting that they flank each other rather than occupy
the same location19 (Fig. S3B).
Notably, a GFP-tagged form of the C-terminal fragment of
HMG20b spanning residues 173–317, which includes the
BRCA2-binding region, is efficiently localized to the cytokinetic
midbody (Fig. 2C). Its accumulation at this site is comparable to
that of full-length GFP-HMG20b expressed at a similar level
(Fig. 2B and D). In contrast, an N-terminal fragment (GFP-
HMG20b 1-112) did not exhibit midbody localization. Interest-
ingly, the C-terminal fragment evenly distributes between the
nucleus and cytoplasm, whereas the full-length protein and the
N-terminal fragment are predominantly nuclear, which is consis-
tent with the presence of a putative NLS (nuclear localization sig-
nal) at the N-terminal region (aa 52–66) of the protein.20 Thus,
our results suggest that a C-terminal fragment of HMG20b
required for complex formation with BRCA2 is sufficient for its
localization to cytokinetic structures.
The C-terminal region is necessary and sufficient for an
essential role of HMG20b in cytokinesis
We have previously shown that depletion of HMG20b leads
to delayed or failed cytokinesis.13 To test whether the C-terminal
region of the protein is involved in this role, we established a
series of HeLa cell clones stably transfected with Tet-inducible
cDNA constructs encoding different regions of HMG20b fused
at their N-termini to a FLAG-epitope tag (Fig. S4). The selected
HeLa cell clones express comparable levels of the different
HMG20b fragments after treatment with the inducer, Doxycy-
cline (Fig. S6). Since the constructs encoding these proteins lack
the untranslated regions (UTR) present in the mRNA for endog-
enous HMG20b, we used 3 different siRNA duplexes (D4, D5
and Q1, Fig. S5) targeting the 3’ UTR of HMG20b mRNA to
deplete endogenous HMG20b. All 3 siRNA duplexes, which
were designed using 2 different algorithms to minimize seed
sequence homologies, showed a similar efficiency in inducing
cytokinesis failure marked by the appearance of multi-nucleate
cells (Fig. S5). We therefore selected the siRNA duplex Q1 for
use in subsequent experiments, and confirmed that it could effi-
ciently deplete endogenous HMG20b protein without affecting
the expression of the stably transfected constructs (Fig. S6).
Notably, doxycyline (Dox)-induced expression of full-length
FLAG-HMG20b protein in 2 independently-derived HeLa cell
clones F2-2 or F2-3 (Fig. S6A) reduced in a statistically signifi-
cant manner the occurrence of multi-nucleated cells marking
cytokinesis failure after endogenous HMG20b depletion
(Fig. 4A, Fig. S7). This result further validates that HMG20b
performs an essential role during normal cytokinesis.13 However,
expression of the N-terminal fragment FLAG-HMG20b 1–112
failed to restore cytokinesis under similar conditions in 3 inde-
pendently-derived cell clones F3-1, F3-6 or F3-8 (Fig. 4B,
Fig. S6B, Fig. S7).
By contrast, expression of the C-terminal fragment FLAG-
HMG20b 173–317 that contains the region required for
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BRCA2-HMG20b complex formation was sufficient to restore
cytokinesis following endogenous HMG20b depletion in 3 inde-
pendently-derived cell clones F4-1, F4-6 or F4-11 (Fig. 4C,
Fig. S6C, Fig. S7). Notably, this C-terminal HMG20b fragment
reduced the frequency of multinucleate cells marking failed cyto-
kinesis to the same extent as full-length HMG20b (compare
Fig. 4A with 4C), suggesting that it is necessary and sufficient to
supplant an essential role of HMG20b during cytokinesis.
We therefore further dissected the functional role of resi-
dues within this region. The C-terminal HMG20b fragments
spanning aa 173–276 (C-terminal D1) and 173–264 (C-ter-
minal D2) not only failed to restore cytokinesis in HMG20b-
depleted cells (Fig. 4D and E, Fig. S6D and E, Fig. S7), but
instead appeared to inhibit cytokinesis in cells treated with a
control siRNA against luciferase (Fig. 4D and E, compare
Luc with LucCDox). This was confirmed in a time-course
Figure 2. The C-terminal region of HMG20b mediates localization to midbody. (A) Localization of HMG20b during cell cycle. Confocal images of HeLa
cells expressing GFP-HMG20b are shown for each cell cycle phase. Enlarged image of midbody is shown as an inset . Scale bar is 5mm. (B) Western blot
showing inducible expression of GFP-HMG20b fragments. b-Actin was probed as a loading control. (C) Confocal images of HeLa cells expressing GFP-
HMG20b fragments (green). MKLP1(red) was immunostained as a midbody marker. Enlarged images of midbody are shown as insets. Scale bar is 5mm.
(D) GFP intensity at midbody normalized to the intensity within total cell area for each GFP-HMG20b fragments. A representative scatter dot plot from 3
independent experiments is shown with mean § s.e.m. Twenty-ﬁve cells were analyzed in each experiment. Statistical signiﬁcance was conﬁrmed for
the indicated pair-wise comparisons using Dunnett’s multiple comparison test (***: P < 0.001).
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experiment where expression of FLAG-HMG20b 173–264
increased the frequency of multinucleate cells marking cytoki-
nesis failure in a time-dependent manner (Fig. 4F). Remark-
ably, the C-terminal HMG20b fragment spanning aa
173–276 (C-terminal D1) has similar BRC5 binding activity
to the fragment 173–317. However, we find that it fails to
restore cytokinesis after depletion of endogenous HMG20b
protein, suggesting that additional C-terminal sequences are
required. Thus collectively, our findings define a C-terminal
region in HMG20b required for complex formation with
BRCA2 that is necessary and sufficient for cytokinesis, and
show that omission of even a small stretch of 41 residues at
the very C-terminus of the BRCA2-binding region is enough
to impair this function.
A cancer-associated mutation in the C-terminal region of
HMG20b disrupts cytokinesis in a dominant manner
Mutations in the HMG20B gene recently detected through
next-generation sequencing of human cancer samples (Catalogue
of Somatic Mutations in Cancer (COSMIC), http://www.
sanger.ac.uk/cosmic21) are shown in Table S1. These mutations
occur in several different forms of human epithelial cancer,
including lung carcinomas, and affect a single HMG20B allele,
Figure 3. Endogenous HMG20b localizes to the cytokinetic midbody. (A) Western blot analysis of control and HMG20b siRNA-treated HeLa cell extracts
using HMG20b monoclonal antibody 1F6. Puriﬁed His-HMG20b protein was used as a positive control and b-Actin was probed as a loading control.
(B) Confocal images of control and HMG20b siRNA-treated HeLa cells stained with anti-HMG20b monoclonal antibody 1F6 (green). MKLP1 (red) was
co-stained as a midbody marker. Enlarged images of midbody are shown as insets. Scale bar is 5mm. (C) Mean intensity of HMG20b staining at midbody.
Results from 50 cells per sample are shown with mean§ s.e.m. (***: P < 0.001, unpaired t test)
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Figure 4. The C-terminal region is necessary and sufﬁcient for an essential role of HMG20b in cytokinesis. (A) Frequency of multinucleate cells was ana-
lyzed in 2 independent HeLa cell clones (F2-2 and F2-3) expressing full-length Flag-HMG20b following treatment with HMG20b siRNA (Q1) and/or Doxy-
cycline (Dox). Means § s.e.m. from 3 independent experiments are shown and >500 cells were analyzed per each sample. Statistical signiﬁcance was
conﬁrmed for the indicated pairwise comparisons using Bonferroni’s multiple comparison test (***: P < 0.001, **: 0.001 < P < 0.01, *: 0.01 < P < 0.05, ns:
P > 0.05). The same treatments (siRNA § Dox) and statistical analysis were applied to Figure 4 (B), (C), (D) and (E). (B) Three independent clones (F3-1,
F3-6, and F3-8) expressing N-terminal (1-112) HMG20b fragment were analyzed for multinucleation frequency. (C) Three independent clones (F4-1, F4-6,
and F4-11) expressing C-terminal (173–317) HMG20b fragments were analyzed for multinucleation frequency. (D) Three independent clones (F5-11, F5-
34, and F5-42) expressing truncated C-terminal fragment D1 (173–276) were analyzed for multinucleation frequency. (E) Three independent clones (F6-
5, F6-8, and F6-9) expressing truncated C-terminal fragment D2 (173–264) were analyzed for multinucleation frequency. (F) Clones F6-8 and F6-9 were
treated with Doxycycline and analyzed for multinucleation frequency every 24 hours for 3 d. >500 cells were analyzed for each sample. Means § s.e.m.
from 3 independent experiments are shown (test for linear trend, **: 0.001 < P < 0.01, *: 0.01 < P < 0.05).
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prompting questions as to whether they affect HMG20b func-
tion despite the presence of a normal allele.
We tested the functional impact of several of these mutations,
including T189S, F192V, A247P and V303I and V312G on the
ability of mutant full-length FLAG-HMG20b to bind to a gluta-
thione S-transferase (GST)-tagged fragment of human BRCA2
aa1613–1781 that contains the BRC5 motif (Fig. 5A; Fig. S8A).
Notably, only one of these mutations (a non-conservative substi-
tution of Ala247 with Pro (A247P)) reduced binding to the
GST-BRCA2 fragment (Fig. 5A; Fig. S8A). Moreover, the
A247P mutation also interferes with the localization of full-
length GFP-HMG20b A247P protein to the cytokinetic mid-
body (Fig. 5B and C). These findings suggest that the cancer-
associated A247P mutation in HMG20b compromises its
normal function in BRCA2 binding and cytokinesis.
Interestingly, conditional expression of FLAG-HMG20b
A247P in HeLa cells proved technically challenging. Few sta-
bly transfected HeLa clones could be isolated in this way,
and those that were, exhibited background levels of multinu-
cleation even when expression of the mutant protein was rela-
tively low before induction with Doxycycline, suggesting that
the mutation had a dominant-negative effect on cytokinesis.
Indeed, as exemplified in the clone A247P-5, Dox-mediated
induction of FLAG-HMG20b A247P or depletion of endoge-
nous HMG20b caused a marked increase in the frequency of
multinucleate cells marking cytokinesis failure, which was fur-
ther accentuated by combining these manipulations (Fig. 5D;
Fig. S8B). Moreover, even transient expression of FLAG-
HMG20b A247P in cells expressing endogenous HMG20b
sufficed to increase the frequency of multinucleate cells
(Fig. 5E; Fig. S8C). Together, these results strongly suggest
that the cancer-associated A247P mutation is not only func-
tionally deleterious, but also that it can induce cytokinesis
failure and aneuploidy in a dominant manner even when
wild-type HMG20b is also present.
Discussion
Our findings identify a C-terminal region of HMG20b that is
necessary and sufficient not only for its localization to the cytoki-
netic midbody, but also for its interaction with the tumor sup-
pressor BRCA2, implicated in the abscission step of cytokinesis.
Indeed, both endogenous and GFP-tagged forms of HMG20b
are recruited to the cytokinetic midbody consistent with partici-
pation in a BRCA2-HMG20b complex that regulates cell divi-
sion. Although GFP-HMG20b co-localizes with midbody
markers such as MKLP1 and Cep55, we observe differences in its
staining pattern that suggest they occupy distinct topologic
domains within the midbody structure. This observation war-
rants future investigation in the light of known mechanisms that
regulate midbody assembly and function.19
We find that C-terminal HMG20b fragments spanning aa
173–276 and 173–264 (which lack a short stretch of residues at
the very C-terminal region), as well as a cancer-associated muta-
tion HMG20b mutant, A247P, not only fail to restore
cytokinesis in HMG20b-depleted cells but also provoke defective
cytokinesis even when endogenous wild-type HMG20b is pres-
ent. This dominant negative effect cannot plausibly be exerted
via competition with endogenous wild-type HMG20b for bind-
ing to BRCA2, since neither the aa 173–264 fragment nor the
point-mutant form of HMG20b exhibit BRC5 binding. There-
fore, we speculate that mutant HMG20b may interfere with the
function of its wild-type counterpart through binding to a cytoki-
netic regulator other than BRCA2. Identification of such a puta-
tive mechanism warrants further investigation, but will require
extensive biochemical studies beyond the scope of the current
work.
In conclusion, our findings provide fresh insight into topical
observations concerning the biological function of the BRCA2-
HMG20b complex in the completion of mitotic cell division by
cytokinesis.13,18,22 BRCA2 interacts with HMG20b via the evo-
lutionarily conserved BRC5 motif,13,23,24 but with other cytoki-
netic mediators such as BCCIP,22 Filamin A, CEP55 and
ESCRT components18 using distinct regions, suggesting that
BRCA2 may serve as a scaffold for the dynamic assembly of a
large, multi-protein complex at cytokinetic structures such as the
midbody.
Importantly, we show that a mutant form of HMG20b
detected in human epithelial cancers acts in a dominant man-
ner to induce cytokinesis failure. Our results suggest that
HMG20B may represent an unusual type of human tumor
suppressor gene, whose heterozygous alteration by mis-sense
mutations may suffice to promote carcinogenesis.25 Our work
also serves to exemplify and substantiate the long-standing
proposal that defects in the completion of cell division may
foster chromosome instability and human carcinogenesis.
These insights collectively raise numerous important issues
warranting future investigation.
Materials and Methods
Protein expression and purification
Various fragments of human HMG20b cDNA (as outlined
schematically in Fig. 1A; Fig. S1A) were cloned into pET21a
vector (MerckMillipore, 69740-3). HMG20b fragments with C-
terminal His-tag were expressed in E. coli BL21 (DE3) (Bioline,
BIO-85032) and purified using Ni-NTA agarose beads (Qiagen,
30210). GST-BRCA2 fragment (1613–1781) containing BRC5
repeat was cloned in pGEX-4T3 vector (GE Healthcare, 28-
9545-52) and purified as described previously.26
Streptavidin pull-down assay
Biotinylated BRC5 peptide (amino acid residues 1661–1695)
was synthesized by Cambridge Research Biochemicals. For the
pull-down assay, 1 nmol of biotinylated peptide bound to Dyna-
beads M-280 Streptavidin (Invitrogen, 11205D) was incubated
with 100 pmol of purified HMG20b fragments in binding buffer
(50mM Tris-HCl (pH 7.4), 150mM NaCl, 1% NP-40, 5mM
EDTA, 10mM NaF, and complete protease inhibitor cocktail
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Figure 5. A cancer-associated mutation in the C-terminal region of HMG20b disrupts cytokinesis in a dominant manner. (A) GST-pull down assay. Flag-
HMG20b mutants expressed in 293T cells were incubated with GST-BRCA2 fragment containing BRC5. Bound proteins were detected by western blotting
using anti Flag antibody. Ponceau S- stained membrane is included in the lower panel to show that equal amount of GST fusion proteins was used for
each sample. (B) Confocal images of HeLa cells expressing wild type or A247P mutant of GFP-HMG20b (green). MKLP1 (red) was immunostained as a
midbody marker. Enlarged images of midbody are shown as insets. Scale bar is 5 mm. (C) Localization of wild type and A247P mutant of GFP-HMG20b at
midbody. A representative scatter dot plot of GFP intensity ratio from 3 independent experiments is shown with mean § s.e.m. Twenty-ﬁve cells were
analyzed in each experiment (***: P < 0.001, unpaired t test). (D) Clone (A247P-5) expressing Flag-HMG20b with A247P mutation was analyzed for multi-
nucleation frequency after HMG20b siRNA (Q1) and/or Doxycycline (Dox) treatment. Means § s.e.m. from 3 experiments are shown and >500 cells were
analyzed per each sample. Statistical signiﬁcance was conﬁrmed for the indicated pairwise comparisons using Bonferroni’s multiple comparison test
(**: 0.001 < P < 0.01, *: 0.01 < P < 0.05, ns: P > 0.05). (E) Multinucleation frequency measured at 72 hours after HeLa cells were transiently transfected
with Flag-HMG20b constructs . Means§ s.e.m. from 4 independent experiments (2 experiments for the vector control) are shown. Transfected cells were
identiﬁed by anti-Flag immunostaining and >200 transfected cells were analyzed per each sample. Wild type and A247P mutant of HMG20b are
compared with the vector control by Dunnett’s multiple comparison test (***: P< 0.001, ns: P > 0.05).
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(Roche, 11873580001)) containing 0.1% BSA for 30 minutes at
room temperature. The beads were washed with binding buffer
to remove unbound proteins and the bound proteins were then
detected by staining with Coomassie brilliant blue R-250 (Bio-
Rad, 161-0436) following electrophoresis using 12% Tris-Gly-
cine gels.
GST pull-down assay
GST-BRCA2 fragment bound to Glutathione Sepharose Beads
(GE Healthcare, 17-0756-01) was incubated with 293T cell
extracts expressing Flag-HMG20b in binding buffer (50mM Tris-
HCl (pH 7.4), 300mM NaCl, 1% NP-40, 5mM EDTA, 10mM
NaF, and complete protease inhibitor cocktail (Roche)) containing
0.1% BSA for 30 minutes at room temperature. The beads were
washed extensively with the binding buffer and bound proteins
were analyzed by western blotting with the indicated antibodies.
siRNA sequences
Luciferase siRNA (control): 5’-CGUACGCGGAAUA-
CUUCGA-3’ (synthesized by Eurofins MWG Operon),
D4: 5’-GGACACAGGGCAGACGAAA-3’ (D-020146-04,
Thermo Scientific),
D5: 5’-CGCGAUACACCCAGAAGAA-3’ (D-020146-05,
Thermo Scientific),
Q1: 5’-CAGCATCCCTTTAGCTTTCAA-3’ (SI00087633,
Qiagen)
Mutagenesis
HMG20b mutant constructs were made by PCR using Accu-
Prime Pfx DNA polymerase (Invitrogen, 12344-024). PCR prod-
ucts were digested with DpnI enzyme and were used to transform
E. coli DH5a. The following primers were used for mutagenesis.
T189S:
Forward 5’CCACCTTCGATGTTCCCATCTTCAGTGAA
GAGTTCTTGGACC3’
Reverse 5’GGTCCAAGAACTCTTCACTGAAGATGGGA
ACATCGAAGGTGG3’
F192V:
Forward 5’CCCATCTTCACTGAAGAGGTCTTGGACC
AAAACAAAGCGCG3’
Reverse 5’CGCGCTTTGTTTTGGTCCAAGACCTCTTC
AGTGAAGATGGG3’
A247P:
Forward 5’GAGGAGCGGAGGACGCTGCCGCTGCAG
CAGCAGCTCCAG3’
Reverse 5’CTGGAGCTGCTGCTGCAGCGGCAGCGTC
CTCCGCTCCTC3’
V303I:
Forward 5’GCACGAGAAGCTCATCATCCGCATCAAG
GAAATCCTGGCC3’
Reverse 5’GGCCAGGATTTCCTTGATGCGGATGATG
AGCTTCTCGTGC3’
V312G:
Forward 5’GGAAATCCTGGCCCAGGGCGCCAGCGA
GCACCTG3’
Reverse 5’CAGGTGCTCGCTGGCGCCCTGGGCC
AGGATTTCC3’
Inducible expression of HMG20b fragments
A Tet-On inducible gene expression system (Clontech,
630922) was used to conditionally express HMG20b fragments.
The indicated HMG20b fragments (as shown in Fig. S4) were
first cloned into EcoRI and BamHI sites of p3xFLAG-CMV-10
vector (Sigma, E7658). The region containing Flag-tag and
HMG20b fragments were amplified by PCR and cloned into
BamHI and MluI sites of pTRE2pur vector. The constructs were
used to transfect HeLa Tet-On advanced cell line (Clontech,
632110) and stable clones were selected with puromycin (1mg/
ml). For expression of GFP-HMG20b fragments, respective
HMG20b cDNA fragments were first cloned into EcoRI and
BamHI sites of pEGFP-C1 vector (Clontech, 6084-1). The
region containing GFP-tag and HMG20b fragments were ampli-
fied by PCR and cloned into BamHI and MluI sites of pTRE2-
pur vector as described above.
siRNA transfection and induction of Flag-HMG20b
fragment expression
Cells were seeded on 6-well plates in the medium with or
without Doxycline (1mg/ml) the day before the transfection with
siRNAs (40 nM) using Lipofectamine 2000 reagent (Invitrogen,
11668-027). Cells were split into 35 mm culture dishes 24 hours
post-transfection and phase-contrast images were taken at
72 hours post-transfection. CDox samples were continuously
incubated with Doxycycline during the experiment.
Transient expression of Flag-HMG20b
Flag-HMG20b constructs were transfected into HeLa or
293T cells using jetPRIME transfection reagent (Polyplus trans-
fection, 114-07) according to the manufacturer’s instruction.
Enumeration of multinucleated cells
Phase contrast images were taken using a Zeiss Axiovert 200M
microscope. Multinuclear cells were counted from phase contrast
images of at least 500 cells per sample. Results from 2 or 3 inde-
pendent experiments were statistically analyzed using GraphPad
Prism software as described in the Figure legends (Figs. 4 and 5D;
Fig. S5). In Fig. 5E, to identify Flag-HMG20b expressing cells
after transient transfection, cells grown on coverslips were stained
with anti-Flag antibody and both phase contrast and fluorescence
images were taken using Zeiss Axiovert 200M microscope.
Immunofluorescence
HeLa Tet-On cell lines containing GFP-HMG20b constructs
were grown on glass coverslips and treated with Doxycycline
(1mg/ml) overnight. Cells were fixed in 4% PFA for 5 min, per-
meabilised with TBS-T (TBS containing 0.1% Triton-X100)
and incubated in blocking solution (2% BSA in TBS-T). The
cells were then incubated with the indicated primary and second-
ary antibodies (diluted in blocking solution) for1 hour and 30
minutes respectively. GFP-HMG20b was stained with anti GFP
antibody (Living Colors A.v. monoclonal antibody JL-8, Clon-
tech, 632381, 1:100). MKLP1 was stained with anti-MKLP1
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rabbit polyclonal antibody (Santa Cruz Biotechnology (N-19, sc-
867), 1:1,000)). Anti-HMG20b monoclonal antibody clone 1F6
and rabbit polyclonal antibody against Cep55 were purchased
from Abnova (1F6: H00010362-M01, 1:500, Cep55:
H00055165-D01, 1:1,000). Tubulin was stained with rat mono-
clonal anti Tubulin antibody (Abcam, ab6161, 1:500). Rabbit
polyclonal anti phospho-Histone H3 (Ser 10) antibody was pur-
chased from Abcam (ab5176, 1:2,500). Secondary antibodies
used were Alexa 488 or 568-conjugated goat IgGs from Invitro-
gen (A11029 and A11036). Images were acquired with Zeiss
LSM510 META confocal microscope and analyzed using Image
J software.
Western blotting
Whole-cell extracts were made using NP-40 lysis buffer
(50mM HEPES (pH 7.4), 100 mM NaCl, 0.5% NP-40,
10 mM EDTA, 20 mM b-glycerophosphate, 1mM DTT, 1mM
sodium orthovanadate, complete protease inhibitor cocktail
(Roche)) and resolved with 4–12% Bis-Tris gel (Invitrogen,
NP0335BOX). The antibodies used were anti-HMG20b (mouse
monoclonal clone 4.21 (anti-BRAF35, Millipore, 05-641),
rabbit polyclonal antibody M1013), anti-Flag mouse monoclonal
antibody M2 (Sigma, F1804), anti-GAPDH (mouse monoclonal
A-3, Santa cruz Biotechnology, sc-137179) and anti-b-Actin
(mouse monoclonal AC-15, Sigma, A5441).
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